Xogenex

Xogenex is a biotechnology company focused on developing transformative gene therapies for cardiovascular diseases, with a primary emphasis on heart failure. The company's lead program, XG-101, utilizes an adeno-associated virus (AAV) vector to deliver the S100A1 gene directly to the myocardium to restore calcium homeostasis and improve cardiac function. By targeting the underlying molecular causes of heart failure rather than just managing symptoms, Xogenex aims to provide long-term therapeutic benefits for patients with reduced ejection fraction. The company's approach is based on decades of research into the role of S100A1 in cardiac physiology and pathophysiology. Xogenex is currently advancing its lead candidate through IND-enabling studies to transition into clinical trials.